COREX

SOVEREIGN BIO-INTELLIGENCE

2025 COMPANY OF THE YEAR

Driving impact across the customer value chain

RECOGNIZED FOR BEST PRACTICES IN THE GLOBAL BIO-INTELLIGENCE INDUSTRY

FROST & SULLIVAN

Table of Contents

Best Practices Criteria for World-class Performance

Frost & Sullivan applies a rigorous analytical process to evaluate multiple nominees for each recognition category before determining the final recognition recipient. The process involves a detailed evaluation of best practices criteria across two dimensions for each nominated company. CoreX excels in many of the criteria in the Bio-Intelligence space.



Bio-Intelligence: An Overview

The pharmaceutical industry is at a critical phase, defined by a vital paradox. While medical science has never been more advanced, a one-size-fits-all approach to drug development yields suboptimal and often dangerous outcomes.[1] Adverse drug reactions (ADR) are a harsh testament to this systemic issue, representing a severe public health crisis. In the United States (US) alone, research estimates ADRs to be a leading cause of mortality, contributing to thousands of deaths annually and placing an immense burden on healthcare systems globally.[2] The root cause of this problem lies in human biological diversity. It is well-documented that a drug's safety and efficacy can vary significantly across different demographic groups, influenced by genetic factors associated with age, sex, and ancestry.[3] For instance, variations in the prevalence of key metabolic enzyme genes, such as CYP2D6 or CYP2C9, across different ethnic populations can significantly alter drug responses. Yet, traditional drug development pipelines have historically overlooked this crucial variability.[4]

For decades, the path to bringing a new drug to market has been notoriously inefficient, fraught with staggering costs and high failure rates. The average cost to develop a new therapeutic drug now exceeds $2 billion, with a timeline that can span over a decade.[5] A primary contributor to this inefficiency is the reliance on preclinical models, particularly animal testing, that frequently fail to predict human responses. Consequently, an estimated 90% of drugs that enter clinical trials ultimately fail, most often due to

[1] https://link.springer.com/article/10.1007/s10516-025-09747-4
[2] https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.859909/
[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC11465127/
[4] https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1180487/full
[5] https://www.fiercebiotech.com/biotech/drug-development-cost-pharma-22b-asset-2024-plus-how-glp-1s-impact-roi-deloitte

unforeseen toxicity or a lack of efficacy in human subjects.[6] This costly attrition highlights a critical need for new paradigms that can provide more accurate, human-relevant predictions long before a candidate drug reaches a patient.

In response to these challenges, a revolutionary new field is emerging at the intersection of artificial intelligence (AI), stem cell biology, and bioengineering. This Bio-AI-powered, or Bio-Intelligence approach reshapes drug discovery and safety assessment. The catalyst for this transformation is the development of New Approach Methodologies (NAM), such as Micro Physiological Systems (MPS), Organoids and Organs-on-Chip. The next generation of these technologies utilizes induced pluripotent stem cell (iPSC)-derived organoids,[7] allowing development of a fully personalized Organ-on-Chip, or when connecting several such miniaturized-organs together often referred to as "Bio-Avatar" or "Patient-on-Chip" (or multi-organ-on-chip) technology. These miniaturized, functional human organ systems, grown from a patient's cells, provide a biologically faithful platform to test drug compounds, recreating human-specific physiology in a laboratory (lab) environment.[8] When linked with sophisticated AI and machine learning algorithms, these platforms can analyze vast, complex biological data to predict a drug's potential for toxicity or efficacy with unprecedented speed and precision.

Additionally, modern machine and deep-learning models, incorporating demographic metadata, improve ADR prediction performance, with area under the curve gains of up to 3.9% when combining chemical, molecular, and demographic features.[9] This paradigm shift has received significant regulatory tailwinds, most notably with the passage of the US Food and Drug Administration (FDA) Modernization Act 2.0, which officially removes the mandate for animal testing and encourages the adoption of scientifically superior, human-based alternatives.[10]

However, this new frontier is not without its own set of challenges. The efficacy of AI models is entirely dependent on the quality and diversity of the data they are trained on, raising concerns about data heterogeneity and the potential for algorithmic bias to perpetuate existing health disparities. Furthermore, the "black box" nature of some complex algorithms presents hurdles for model interpretability and regulatory acceptance, demanding a transparent and ethically robust framework for development and deployment.[11]

It is at this nexus of immense opportunity and complex challenges that CoreX establishes leadership. The company has in-licensed and integrated several related cutting-edge technologies and is developing the first global personalized drug platform that would better predict toxicity and efficacy across age, sex, and race. Positioned strategically in the United Arab Emirates (UAE) and the Gulf Cooperation Council, CoreX develops tools aligned with evolving regulatory NAMs and aiming for major industry impact within the next few years.

[6] https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/
[7] https://pmc.ncbi.nlm.nih.gov/articles/PMC10250752/
[8] https://pmc.ncbi.nlm.nih.gov/articles/PMC10465229/
[9] https://www.nature.com/articles/s41598-024-74505-2.pdf
[10] https://www.congress.gov/bill/117th-congress/senate-bill/5002
[11] https://blog.drugbank.com/unleashing-ai-in-drug-discovery-prospects-and-challenges/

Addressing Global Healthcare Disparities using Cutting-edge Bio-Intelligence Solutions

CoreX stands at the forefront of AI, organoid biology, and genomic diversity. The company leverages Bio-Intelligence technologies and transforms them into a scalable, UAE regionally adapted drug development platform.[12] It tailors this innovation further into unique genetic and demographic profiles of underrepresented populations. CoreX's platform aims to simulate and predict drug responses across diverse ethnicities and sub-populations with unprecedented precision by integrating stem cell-derived organoids, multi-omic datasets, and advanced machine learning algorithms. This approach addresses longstanding gaps in traditional drug development, including limited trial diversity and the global burden of ADRs. Leveraging strategic collaborations with regional giants and world-leading genome sequencing initiatives, the company delivers safer, smarter drugs that reflect real human diversity at a population level.

> *"CoreX's Bio-Intelligence engine represents a strategic leap for the UAE. Building on UAE's world's largest genome project, it delivers a platform for developing safer, faster, population-specific drugs. By uniquely integrating cutting-edge AI with organ-chip biology, and guided by pharma and tech leaders, it attracts pharma business, enhances UAE's health security, and positions it as a hub for AI drug development."*
>
> ***- Neeraj Jadhav***
> ***Senior Industry Analyst & Team Lead,***
> ***Growth Opportunity Analytics***

CoreX understands that the pharmaceutical value chain suffers from the absence of population-specific safety and efficacy data for drugs entering new markets or being repurposed for diverse demographics. While the global drug development paradigm traditionally relies on generalized clinical trials centered around homogenous patient profiles, the company recognizes that this "average patient" model fails to capture the nuances of genetic diversity, metabolic variability, and region-specific health profiles, particularly in underrepresented markets like India, the UAE, and broader Middle East and North Africa (MENA) regions.

The company's Bio-Intelligence engine uses a hybrid in-vitro/in-silico approach that synergizes AI-driven population modeling with organ-on-chip stem cell biology, delivering a groundbreaking solution to this unmet need. CoreX's AI algorithms intelligently cluster populations into subgroups based on disease susceptibility, metabolic traits, and genetic markers by leveraging large-scale genomic, clinical, and behavioral datasets. For example, from a pool of millions, the platform selects representative individuals (ranging from 50 to 1,000 profiles) who encapsulate the biological diversity of a target population. The company's proprietary methods then convert blood-derived iPSCs into miniaturized three-dimensional (3D) organoids or organs-on-chip, replicating key organs such as the liver, heart, kidney, and brain. This capability enables high-throughput, AI-augmented testing of drug-organ interactions, providing clinically actionable pharmacokinetic (PK) and pharmacodynamic (PD) insights without the need for extensive live human trials across every geography, revealing demographic-specific differences in drug metabolism that might have remained undetected in traditional trials. This capability eliminates reliance on data derived from non-representative populations, such as standard Caucasian male cohorts, ensuring that safety and efficacy data are directly relevant to the target demographic.

[12] https://www.mediaoffice.abudhabi/en/health/institute-for-healthier-living-abu-dhabi-partners-with-corex-to-establish-the-uaes-first-bio-intelligence-engine-based-on-a-specific-population/

CoreX provides a strategic advantage to regulators, insurance providers, and pharmaceutical companies seeking to mitigate trial failures, reduce development timelines, and ensure regulatory compliance by delivering population-specific PK/PD profiles before launch. Furthermore, the company's tactic supports pharmaceutical marketing teams in confidently repurposing existing drugs for new regions by offering robust, regionally adapted efficacy data, thereby reducing market entry risks and enabling precise healthcare outcomes. Likewise, CoreX's focus on functional, biology-driven testing transcends inferential genomics, offering a more direct and predictive assessment of drug performance on actual human biology. This competence enhances the precision of safety profiling, reduces clinical trial costs, and improves payer acceptance by aligning therapeutic data with the unique needs of specific populations.

Frost & Sullivan commends CoreX's innovative global drug localization approach, addressing unmet needs across regulatory, clinical, and commercial dimensions. The company sets a novel standard for demographic-specific drug safety and efficacy assessment.

Enhancing Patient-centric Outcomes with Robust Predictive Models

CoreX implements best-in-class practices through its structured, repeatable, and scalable Bio-Intelligence platform architecture, meticulously designed to drive success in demographic-specific drug safety and clinical prediction. The company's proprietary two-input, three-step framework, "Generate, Train, and Predict", embodies a process-centric approach that fuses cutting-edge AI with biological rigor, delivering actionable insights that seamlessly translate across diverse drug candidates and patient models.

The platform first deeply studies hundreds of known FDA-approved drugs, generating a vast, unique dataset by documenting and capturing millions of interactions of these known drugs with stem-cell-derived 3D organ-on-chip models of specific patients. This foundational dataset, generated in Step 1 (Generate), serves as a comprehensive reference of toxicological signatures, biomarker patterns, and dose-response thresholds across key organ systems, such as the liver, heart, and kidney, for different specific patients.

In Step 2 (Train), CoreX trains its deep learning engine on this dataset, enabling the AI to recognize complex, nonlinear relationships between molecular structures and biological responses. The training process extracts nuanced toxicity signatures, identifies dose sensitivities, and flags early warning biomarkers, creating a robust AI model primed for predictive performance.

The platform realizes scalability and consistency in Step 3 (Predict), where it evaluates new drug candidates or patient-derived organoid models. The AI systematically assesses drug-organ interactions, providing precise predictions on safety, toxicity, and personalized efficacy.

Beyond technical robustness, CoreX institutionalizes a multi-layered innovation stack that integrates seamlessly with Abu Dhabi's genomic and biotech network. This stack includes:

- **Genomics Layer**: Harnesses the Abu Dhabi Genome Program for region-specific genomic profiling.
- **iPSC Banking Layer**: Creates a scalable repository of patient-derived pluripotent stem cells.
- **Organoid Layer:** Develops functional 3D models of liver, heart, kidney, and brain for comprehensive organ-level testing.

- **Drug Testing Layer**: Conducts organ-specific assessments of therapeutic efficacy and off-target toxicity.
- **AI Layer**: Unifies multi-omic data streams to generate real-time, predictive outputs for stakeholders across the pharmaceutical value chain.

Furthermore, CoreX strengthens its executional excellence through a global coalition of co-founding partners, including regional anchors within the UAE[1212] biotechnology infrastructure and collaborations with international pharmaceutical and healthcare giants. This neutral, integrative platform model guarantees scalable deployment of the company's Bio-Intelligence capabilities while fostering industry-wide alignment on demographic-specific drug safety standards.

Through these meticulously designed processes, tools, and collaborative frameworks, CoreX establishes a repeatable and scalable ecosystem that consistently delivers predictive accuracy, operational efficiency, and population-specific relevance.

Securing Market Leadership through a Robust Partnership Model

CoreX boasts a calculated and multi-pronged strategy to secure an unassailable position in the Bio-Intelligence space, through in-licensing and integrating key technologies. These include Kidney-on-Chip technology from NumaBio (formerly Nortis), a globally validated platform recognized by the National Institutes of Health through the National Center for Advancing Translational Sciences[13], and selected by NASA for tests in space[14]. Similarly, by in-licensed cutting-edge iPSC-based liver organoid technologies, this enables CoreX to simulate liver functions across specific ethnicities, an unprecedented advancement that addresses population-specific variability in drug response. These capabilities further expand CoreX's organ portfolio, enabling more comprehensive, multi-organ drug safety modeling. By moving beyond generic or animal-based models, it establishes a new industry benchmark for biological relevance in drug safety testing.

CoreX's leadership agenda extends beyond technology, manifesting in the formation of a coalition[12] of elite partners across AI, genomics, longevity science, and public health, each selected to secure its market positioning and operational scalability. Key partners include:

- The **Institute for Healthier Living Abu Dhabi (IHLAD)**[15,12], world's first government-licensed healthy longevity medicine and research center, and equipped with cutting-edge laboratories, scientific talent, and privileged access to the Abu Dhabi Genome Program. Its board brings together senior leaders from Abu Dhabi's largest institutional investors and corporates — including Mubadala, ADQ, FAB and Aldar — collectively overseeing more than $900 billion in assets. Led by Dr. Nicole Sirotin, a globally recognized longevity expert.
- The **Abu Dhabi Department of Health**, steward of one of the world's largest genomic databases, with over 800,000 fully sequenced genomes forming an important part of the backbone of CoreX's AI-guided demographic modeling.

[13] https://ncats.nih.gov/news-events/news/tissue-chip-kidney-cells
[14] https://newsroom.uw.edu/news-releases/soon-kidneys-chip-will-rocket-space-station
[15] https://www.ihlad.ae

- **M42 Diagnostics**, part of M42, a powerhouse joint venture between G42 (an AI leader backed by a $1.5 billion Microsoft investment) and Mubadala, collaborating on delivering diagnostic aspects of CoreX's offerings.
- **Mohamed bin Zayed University of Artificial Intelligence (MBZUAI)**[16], recognized as a leading university in AI research, has a longstanding collaboration and joint top-tier AI scientific publication[17] with the Bio-AI technology that underlies CoreX, aiming to co-develop AI frameworks tailored to population-specific drug safety modeling.
- The **Stem Cell Center (Abu Dhabi)**, a key enabler of CoreX's iPSC banking and organoid biomanufacturing capabilities, provides the biological infrastructure necessary for scalable deployment.

By developing this consortium, CoreX establishes itself at the epicenter of the region's genomic and biotech innovation ecosystem, strengthening its platform with capabilities that are difficult for new entrants to replicate.

Frost & Sullivan admires CoreX's strategic alliances and relentless focus on technological integration. These feats allow the company to architect the future of Bio-AI-driven drug development, cementing its role as the crucial platform for safe, personalized, and regionally adapted therapeutics.

Maximizing ROI with Breakthrough Predictive Capabilities

CoreX revolutionizes the economics of drug development through its Bio-AI-powered platform[18], enabling pharmaceutical companies to optimize existing drug portfolios with precision, speed, and cost efficiency unmatched by traditional research and development (R&D) models. The company's hybrid in-silico/in-vitro approach accelerates time-to-insight and ensures a high return on investment (ROI) across the entire drug development and commercialization lifecycle.

CoreX anchors its value proposition on two transformative business outcomes:

Population-level Drug Insight Generation

CoreX empowers pharmaceutical companies to repurpose and adapt existing drugs for new markets by generating granular, PK/PD insights. Unlike conventional models that rely on average PK data, the company's platform investigates subgroup-specific responses, uncovering critical safety and efficacy nuances based on ethnicity, genetic biomarkers, and metabolic traits. This capability is instrumental in identifying scenarios where drugs, previously deemed safe in certain populations, pose risks in other ethnic cohorts, and vice versa. CoreX also enables personalized dosing strategies, demonstrating therapeutic outcomes with reduced dosages (sometimes as low as a quarter of the standard dose) for patients with specific metabolic profiles. This level of personalization generates substantial cost savings for healthcare systems, insurers, and pharmaceutical stakeholders.

[16] https://mbzuai.ac.ae/about/
[17] https://dl.acm.org/doi/10.5555/3737916.3742077
[18] https://www.sciencedirect.com/science/article/pii/S1359644623000314

Drug Optimization for Specific Populations

CoreX extends its platform's utility to molecular-level optimization, allowing pharmaceutical companies to potentially modify existing drug structures for enhanced performance in targeted populations. The company aims to identify atomic-level modifications that significantly improve a drug's safety and efficacy for distinct ethnic groups. This capability represents a paradigm shift from the conventional one-size-fits-all model to regionally optimized therapeutics.

Furthermore, the CoreX platform demonstrates exceptional data and screening capabilities:

- **12 million** microscopy images captured
- **10,000** miniature organs screened
- **120 million** sensor data points collected
- **50,000** miniature organs processed per year
- Up to **1,000** drugs evaluated annually
- **250** unique patient-derived stem cell models integrated per year
- Generates **270,000** new data points (images and analytics) daily

As an example of CoreX's Bio-Intelligence Engine potential impact on R&D efficiency, it now accurately discerns organ-toxic drugs like Tolcapone's hepatotoxicity, while accurately flagging as safe its structural analog, Entacapone, which is only a few atoms different. This precise structure-to-toxicity differentiation enables pharmaceutical companies to significantly minimize risk in their portfolios early on, avoiding costly late-stage failures.

> *"CoreX supports its Bio-AI platform with a portfolio of over 30 patents, safeguarding key technological innovations that redefine the price-performance equation in drug development. One of its most transformative capabilities is the non-invasive viability assessment of organoids, a patented AI-driven technique that continuously monitors organoid health using thousands of microscopy images."*
>
> ***- Rabin Dhakal***
> ***Best Practices Research Analyst***

Moreover, CoreX supports its Bio-AI platform with a portfolio of over 30 patents, safeguarding key technological innovations that redefine the price-performance equation in drug development. One of its most transformative capabilities is the non-invasive viability assessment of organoids[19], a patented AI-driven technique that continuously monitors organoid health using thousands of microscopy images. This breakthrough eliminates invasive endpoint assays, reducing time and resource expenditures while ensuring real-time viability insights.

CoreX's personalized iPSC-derived organoids represent another leap in individualized drug safety testing. It transforms a simple blood sample into functional models of the liver, heart, Kidney and brain, enabling precise, patient-specific assessment of drug toxicity. These organoids are not merely theoretical models; the company's proprietary protocols ensure organ-level functionality suitable for high-fidelity drug testing, a feat previously unachievable without invasive tissue biopsies.

[19] https://www.biorxiv.org/content/10.1101/2025.03.09.642246v2

CoreX uses a multi-organ testing architectures, where a drug tested is first applied onto a miniaturized liver model of a specific individual patient and is metabolized by this liver, and assesses the toxicity of that drug and its metabolites in brain organoids. This tactic uncovers toxicities that static, single-organ systems fail to detect[20].

The company's high-functionality personalized liver is another industry-first innovation, delivering unmatched accuracy in detecting Drug Induced Liver Injury (DILI), eliminating the dependency on invasive tissue biopsies, making personalized drug testing scalable and clinically relevant, and augmented by additional related patented technologies.[21,22]

Additionally, CoreX's beating heart organoid model, developed from human iPSC-derived cardiomyocytes, exhibits spontaneous contractions, enabling scalable, accurate, testing of cardiotoxicity and arrhythmia-related drugs, and is fully compatible with microscopy-based electrophysiological measurements. Over 100 peer-reviewed publications have recognized iPSC-cardiomyocytes as a benchmark platform for cardiotoxicity screening[23], and so this model provides pharmaceutical companies with an unprecedented level of predictive accuracy in cardiac safety profiling, including within populations.

CoreX' Bio-AI Platform is based on world-leading technologies that CoreX has in-licensed and integrated from QurisAI (Boston USA), NortisBio (Seattle, USA), Drug Interaction Analysis (Switzerland), Functional Genomic Oncology (UK), iPSC-tech (Japan), and others.

Frost & Sullivan is impressed with CoreX for delivering actionable, population-specific insights at a fraction of the time and cost, providing its clients with a superior ROI that encompasses regulatory compliance and market access, reimbursement optimization, and accelerated innovation cycles.

Building Market Trust through Proven Validation and Predictive Precision

CoreX offers pharmaceutical partners a streamlined and data-rich platform that combines in-vitro human organ models with AI-driven predictive analytics. Its platform not only provides industry-best personalized drug safety assessment, but also boasts a live dashboard that presents comprehensive deep-science data and analysis that underlies it, including drug safety assessments, fusing biochemical, enzymatic, and high-content imaging data into an easily navigable interface. This capability empowers clients to visualize and act upon complex safety and efficacy data without navigating the logistical challenges of traditional preclinical models.

Several top pharmaceutical companies have validated the accuracy of the Bio-AI technology that underlies CoreX's platform. Merck reported results of a blind evaluation of the Bio-AI engine that underlies CoreX's platform against its internal preclinical models (Bioconvergence at Merck: how AI and advanced 3D cell models are improving hepatotoxicity predictions, CAMS 2024)[24].

[20] https://www.sciencedirect.com/science/article/pii/S075333222500215X
[21] https://pubs.acs.org/doi/10.1021/acsomega.4c04101
[22] https://pubs.acs.org/doi/10.1021/acsomega.4c06237
[23] https://pubmed.ncbi.nlm.nih.gov/33612039/
[24] https://www.ats.cam.ac.uk/cambridge-alliance-medicines-safety/cams-events

"Bio-AI is the best DILI prediction in Merck's toolbox. It flags liver toxicity that all our pre-clinical 2D and 3D models completely missed!"

Merck, CAMS 2024

Merck's blind evaluation of the Bio-AI showed that it accurately predicted DILI in 92% (11 out of 12) compounds, far surpassing Merck's own predictive capabilities, which flagged only 25%. The Bio-AI also successfully identified toxicities that led to failures in animal testing, Phase 1 and Phase 3 clinical trials, including Merck's Bruton's tyrosine kinase inhibitor drug, Evobrutinib, highlighting its role as a critical risk-mitigation technology that can potentially save hundreds of millions of dollars for a single drug program.

"We are looking forward to exploring how the Bio-AI platform can advance our drug development and testing programs. If we could better focus on developing safe and effective drug candidates, we would be able to reduce significant time and cost investments."[25]

CEO of Healthcare, Merck

In January 2025, Merck announced that it is adopting this Bio-AI platform to test its small molecule candidates prior to entering them into clinical trials.[26]

Similarly, a global top five pharma company conducted a blind assessment of the Bio-AI that underlies CoreX's platform with five clinical compounds, where the Bio-AI correctly identified four out of five liver toxicity cases, outperforming the top-pharma's internal accuracy. In a broader evaluation involving 300 known FDA-classified drugs, the Bio-AI achieved an 87% specificity and 75% sensitivity, metrics that exceeded recent FDA's recently published benchmark (DILIFerence) [27], as well as recently published industry NAM benchmark.[28] Following these results, AstraZeneca BVH accepted the Bio-AI into its collaboration program in its Sweden facility.[29]

In a further dramatic validation, the Bio-AI that underlies CoreX platform has accurately predicted liver toxicity risk of Pfizer's lead obesity drug Danuglipron (Pfizer's oral GLP-1 candidate) nine months before Pfizer announce its failure in clinical trial.[30] While the liver toxicity was extremely rare – occurred in only one patient out of 1400 patients in the clinical trial – the Bio-AI correctly predicted it, in a blinded-test, nine months before the drug's failure in clinical trials. The Bio-AI scored it as a high-risk Drug-induced Liver Injury (DILI)-positive compound, achieving a critical prediction score of 0.74 and uncovering mechanistic toxicity structural alerts through in-silico and in-vitro layers. This prediction long before the clinical failure is especially powerful for an AI platform, ensuring that the AI predictor is indeed accurate and unbiased, negating any possibility of data-contamination or overfitting.

An additional striking asset of CoreX, is its proprietary oral obesity drug program. Developed using CoreX's Bio-Intelligence engine, it addresses a $20 billion annual unmet market need in obesity care, of over 50% of all current glucagon-like peptide-1 (GLP-1) users who drop-out within the first year of use due to GLP's

[25] https://thehealthcaretechnologyreport.com/top-companies/quris-ai/
[26] https://www.contractpharma.com/breaking-news/merck-kgaa-adopts-bio-ai-clinical-prediction-platform/
[27] https://www.sciencedirect.com/science/article/pii/S1359644625001655
[28] https://pubmed.ncbi.nlm.nih.gov/39397666/
[29] https://www.azbioventurehub.com/news/2024/quris-ai-joins-az-bioventurehub.html
[30] https://www.wsj.com/health/pharma/pfizer-halts-development-of-weight-loss-pill-f3045796

side-effects.[31] CoreX's obesity drug program is non-GLP, non-injected, based on endocannabinoid modulation, and aims to deliver strong weight loss without muscle loss or safety issues that derailed earlier CB1 drugs, and has shown up to 32% body-weight reduction with broad metabolic benefits in obese animal models. Importantly, it has shown an excellent safety profile, using CoreX's underlying Bio-AI, which accurately predicted the safety failure of Pfizer's obesity drug. CoreX's obesity drug is expected to reach Phase-1b within 18 months, and is part of a patent portfolio of 90 related molecules, addressing multiple indications.

Early-stage acquisitions of obesity drug programs are at an all-time high, having surged from $1.1 billion (Novo Nordisk, 2023), through $5.3 billion (Roche, 2024), to $10 billion (Pfizer, November 2025), underscoring an escalating global frenzy for differentiated, non-GLP obesity therapies. For CoreX, and for the UAE, these achievements represent a high-value asset with potential for massive near-term return, as well as a demonstration of the power of Bio-Intelligence to develop safer, faster, population-tailored drugs, with special emphasis on longevity related ones.

The reputed Healthcare Technology Report named CoreX's underlying Boston-based Bio-AI technology as world's top #25 in Biotechnology.[32] And it won BioPharma industry's highest SCRIP Innovation Award, in competition with all the world's biotech and pharma companies, for "closing the clinical gap", the ability to predict which drug will be safe for whom, before expensive clinical trials.[33]

CoreX establishes a formidable brand identity as a scientific pioneer at the intersection of AI-driven drug safety and demographic-specific pharmacology. Its successful validations with leading pharmaceutical companies signal market confidence in its differentiated technology stack. Further enhancing its brand prestige is the company's integration with the UAE's national initiatives in AI and biotechnology. CoreX is strategically aligning with the development of UAE's 'Stargate' AI supercomputing center[34], projected to be the world's most powerful AI infrastructure, positioning itself to leverage its unprecedented computational capabilities for scaling predictive drug safety assessments once operational. The company's proactive partnerships across genomics, AI, and healthcare infrastructure enable it to project a brand identity that is future-ready, globally scalable, and scientifically authoritative.

The company's leadership team further amplifies its brand equity. With scientific icons such as Professor's Aaron Ciechanover (Nobel Laureate) and Robert Langer (Co-founder of Moderna) steering CoreX's scientific vision, alongside seasoned industry executives like Michel Vounatsos (former CEO, Biogen) and Henry McKinnell (former CEO, Pfizer), the company projects a strong image of scientific excellence and executive gravitas. This global leadership is anchored by robust local management, including founder and Global CEO Isaac Bentwich M.D. (Emirati resident) and co-founder and President Sarah Miller (formerly G42 Healthcare, with over 15 years of UAE healthcare leadership), together forming a powerhouse leadership that infuses confidence among pharmaceutical partners.

Rather than positioning itself as a conventional service provider, CoreX fosters brand loyalty through its unique role as a co-development partner, enabling pharmaceutical companies to mitigate clinical risks

[31] https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829779
[32] https://thehealthcaretechnologyreport.com/top-companies/quris-ai/
[33] https://www.citeline.com/en/resources/citeline-announces-winners-of-the-2023-scrip-awards
[34] https://guildhall.agency/stargate-uae-openai-nvidia-ai-hub

and accelerate market entry with higher confidence. Frost & Sullivan firmly believes that this collaborative, high-value approach makes the company a trusted ally in the evolution of AI-powered precision medicine.

Conclusion

The pharmaceutical industry is grappling with the inefficiencies of generalized drug development and the rising imperative for precision medicine. CoreX is a significant innovator that connects artificial intelligence (AI)-driven population modeling with biologically representative organ-on-chip systems, addressing one of the most pressing and persistent challenges in healthcare: the lack of data regarding population-specific drug safety and efficacy. The company meticulously engineered "Generate, Train, and Predict" framework, safeguarded by a robust portfolio of proprietary technologies and over 30 patents, offers a scalable, repeatable, and clinically relevant solution that bridges critical gaps in the drug development lifecycle. CoreX's platform enhances predictability and radically optimizes the cost-performance equation for pharmaceutical stakeholders, enabling faster, safer, and more tailored drug launches into diverse demographic markets.

CoreX demonstrates leadership focus with strategic acquisitions, elite partnerships, and active participation in the United Arab Emirates' (UAE) expansive biotechnology and AI ecosystem, ensuring long-term defensibility and market relevance. With successful validations from industry giants like Merck and AstraZeneca, the company's reputation as a credible and customer-focused innovator continues to gain momentum, supporting its brand equity in a highly competitive space.

CoreX's Bio-Intelligence engine represents a strategic leap for the UAE[12]. Building on UAE's world's largest genome project, it delivers a platform for developing safer, faster, population-specific drugs. By uniquely integrating cutting-edge AI with organ-chip biology, and guided by pharma and tech leaders, it attracts pharma business, enhances UAE's health security, and positions it as a hub for AI drug development.

With its strong overall performance, CoreX earns Frost & Sullivan's 2025 Global Company of the Year Recognition in Bio-Intelligence.

What You Need to Know about the Company of the Year Recognition

Frost & Sullivan's Company of the Year Recognition is its top honor and recognizes the market participant that exemplifies visionary innovation, market-leading performance, and unmatched customer care.

Best Practices Recognition Analysis

For the Company of the Year Recognition, Frost & Sullivan analysts independently evaluated the criteria listed below.

Visionary Innovation & Performance

Addressing Unmet Needs: Customers' unmet or under-served needs are unearthed and addressed to create growth opportunities across the entire value chain

Visionary Scenarios Through Megatrends: Long-range scenarios are incorporated into the innovation strategy by leveraging mega trends and cutting-edge technologies, thereby accelerating the transformational growth journey

Leadership Focus: The company focuses on building a leadership position in core markets to create stiff barriers to entry for new competitors and enhance its future growth potential

Best Practices Implementation: Best-in-class implementation is characterized by processes, tools, or activities that generate consistent, repeatable, and scalable success

Financial Performance: Strong overall business performance is achieved by striking the optimal balance between investing in revenue growth and maximizing operating margin

Customer Impact

Price/Performance Value: Products or services offer the best ROI and superior value compared to similar market offerings

Customer Purchase Experience: Purchase experience with minimal friction and high transparency assures customers that they are buying the optimal solution to address both their needs and constraints

Customer Ownership Excellence: Products and solutions evolve continuously in sync with the customers' own growth journeys, engendering pride of ownership and enhanced customer experience

Customer Service Experience: Customer service is readily accessible and stress-free, and delivered with high quality, high availability, and fast response time

Brand Equity: Customers perceive the brand positively and exhibit high brand loyalty, which is regularly measured and confirmed through a high Net Promoter Score®

Best Practices Recognition Analytics Methodology

Inspire the World to Support True Leaders

This long-term process spans 12 months, beginning with the prioritization of the sector. It involves a rigorous approach that includes comprehensive scanning and analytics to identify key best practice trends. A dedicated team of analysts, advisors, coaches, and experts collaborates closely, ensuring thorough review and input. The goal is to maximize the company's long-term value by leveraging unique perspectives to support each Best Practice Recognition and identify meaningful transformation and impact.

		VALUE IMPACT	
STEP		WHAT	WHY
1	**Opportunity Universe**	Identify Sectors with the Greatest Impact on the Global Economy	Value to Economic Development
2	**Transformational Model**	Analyze Strategic Imperatives That Drive Transformation	Understand and Create a Winning Strategy
3	**Ecosystem**	Map Critical Value Chains	Comprehensive Community that Shapes the Sector
4	**Growth Generator**	Data Foundation That Provides Decision Support System	Spark Opportunities and Accelerate Decision-making
5	**Growth Opportunities**	Identify Opportunities Generated by Companies	Drive the Transformation of the Industry
6	**Frost Radar**	Benchmark Companies on Future Growth Potential	Identify Most Powerful Companies to Action
7	**Best Practices**	Identify Companies Achieving Best Practices in All Critical Perspectives	Inspire the World
8	**Companies to Action**	Tell Your Story to the World (BICEP*)	Ecosystem Community Supporting Future Success

*Board of Directors, Investors, Customers, Employees, Partners

About Frost & Sullivan

Frost & Sullivan is the Growth Pipeline Company™. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service™ provides the CEO and the CEO's growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.

The Growth Pipeline Generator™

Frost & Sullivan's proprietary model to systematically create ongoing growth opportunities and strategies for our clients is fuelled by the Innovation Generator™.

Learn more.

Key Impacts:

- **Growth Pipeline:** *Continuous Flow of Growth Opportunities*
- **Growth Strategies:** *Proven Best Practices*
- **Innovation Culture:** *Optimized Customer Experience*
- **ROI & Margin:** *Implementation Excellence*
- **Transformational Growth:** *Industry Leadership*

The Innovation Generator™

Our 6 analytical perspectives are crucial in capturing the broadest range of innovative growth opportunities, most of which occur at the points of these perspectives.

Analytical Perspectives:

- Megatrend (MT)
- Business Model (BM)
- Technology (TE)
- Industries (IN)
- Customer (CU)
- Geographies (GE)